SKYE — Skye Bioscience, Inc.

SKYE Bioscience, Inc. Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: As of September 30, 2025, SKYE had cash and cash equivalents totaling $35.3 million, expected to fund operations and clinical milestones into 2027.
• R&D Expenses: Increased to $9.4 million from $4.9 million in Q3 2024, primarily due to clinical trial costs and increased manufacturing expenses.
• General and Administrative Expenses: Decreased to $3.9 million from $4.6 million in Q3 2024, attributed to lower consulting fees and reduced salaries.
• Net Loss: Reported at $12.8 million, compared to $3.9 million in Q3 2024, with non-cash share-based compensation remaining consistent at $1.9 million.

2. Strategic Updates and Business Highlights

• Nimazumab Development: The company is focused on advancing the Nimazumab program, with insights from the Phase 2a CBEYOND study guiding future clinical strategies.
• Combination Therapy: Recent data indicated that Nimazumab combined with semaglutide resulted in an additional 3% weight loss at 26 weeks, with significant improvements in body composition metrics.
• Safety Profile: No neuropsychiatric adverse events were reported, reinforcing confidence in the safety of higher dosing.
• Manufacturing and CMC: Progress is being made in optimizing manufacturing processes to reduce costs and improve scalability.

3. Forward Guidance and Outlook

• Clinical Milestones: The company anticipates releasing data from the 26-week extension study in late Q1 2026, which will provide further insights into the long-term efficacy and safety of Nimazumab.
• Dose Optimization: Plans to evaluate higher dosing strategies in future studies, with an emphasis on understanding the pharmacokinetics and pharmacodynamics (PKPD) to maximize efficacy.
• Investor Engagement: SKYE plans to present at multiple investor conferences and scientific meetings in 2026 to share new data and enhance visibility.

4. Bad News, Challenges, or Points of Concern

• Increased Net Loss: The significant rise in net loss year-over-year raises concerns about the sustainability of current spending levels.
• Small Patient Cohort: The 43 patients enrolled in the 26-week extension study may be insufficient for drawing statistically significant conclusions, raising questions about the robustness of future data.
• Regulatory Pathway: Uncertainty remains regarding the need for monotherapy approval before pursuing maintenance therapy, which could complicate the development timeline.

5. Notable Q&A Insights

• Weight Loss and Exposure: Analysts inquired about the relationship between drug exposure and weight loss, with management indicating that higher doses could lead to better outcomes based on preliminary data.
• Regulatory Considerations: The need for monotherapy approval before maintenance therapy was confirmed, highlighting the complexity of navigating regulatory requirements.
• KOL Feedback: Positive reactions from key opinion leaders (KOLs) regarding the combination data and safety profile were noted, suggesting strong interest in the potential market for Nimazumab.
• Safety Concerns: Questions about potential CNS side effects at higher doses were addressed, with management expressing confidence in the safety profile based on existing data.

Overall, SKYE Bioscience is making significant strides in its clinical development of Nimazumab, though it faces challenges related to financial losses and the need for robust patient data in ongoing studies.